The Global Landscape of Esophageal Squamous Cell Carcinoma and Esophageal Adenocarcinoma Incidence and Mortality in 2020 and Projections to 2040: New Estimates From GLOBOCAN 2020

Eileen Morgan 1, Isabelle Soerjomataram 2, Harriet Rumgay 2, Helen G Coleman 3, Aaron P Thrift 4, Jérôme Vignat 2, Mathieu Laversanne 2, Jacques Ferlay 2, Melina Arnold 2
Affiliations Expand
PMID: 35671803 DOI: 10.1053/j.gastro.2022.05.054

Abstract

Background & aims: The aim of this study was to provide an overview of the burden of esophageal cancer in 185 countries in 2020 and projections for the year 2040.

Methods: Estimates of esophageal cancer cases and deaths were extracted from the GLOBOCAN database for 2020. Age-standardized incidence and mortality rates were calculated overall, by sex, histologic subtype (adenocarcinoma [AC] and squamous cell carcinoma [SCC]), country, and level of human development for 185 countries. The predicted burden of incidence and mortality in 2040 was calculated based on global demographic projections.

Results: Globally, there were an estimated 604,100 new cases of, and 544,100 deaths from, esophageal cancer in 2020, corresponding to age-standardized incidence and mortality rates of 6.3 and 5.6 per 100,000, respectively. Most cases were SCCs (85% [512,500 cases]) and 14% (85,700 cases) were ACs. Incidence and mortality rates were 2- to 3-fold higher in male (9.3 and 8.2, respectively) compared with female (3.6 and 3.2, respectively) individuals. Global variations in incidence and mortality were observed across countries and world regions; the highest rates occurred in Eastern Asia and Southern and Eastern Africa and the lowest occurred in Western Africa and Central America regions. If rates remain stable, 957,000 new cases (141,300 AC cases and 806,000 SCC cases) and 880,000 deaths from esophageal cancer are expected in 2040.

Conclusions: These updated estimates of the global burden of esophageal cancer represent an important baseline for setting priorities in policy making and developing and accelerating cancer control initiatives to reduce the current and projected burden. Although primary prevention remains key, screening and early detection represent important components of esophageal cancer control in high-risk populations.

Keywords: Cancer Prevention; Epidemiology; Esophageal Cancer.

PubMed Disclaimer

Similar articles

  • Global incidence of oesophageal cancer by histological subtype in 2012.

    Arnold M, Soerjomataram I, Ferlay J, Forman D.Gut. 2015 Mar;64(3):381-7. doi: 10.1136/gutjnl-2014-308124. Epub 2014 Oct 15.PMID: 25320104
  • Global variations in lung cancer incidence by histological subtype in 2020: a population-based study.

    Zhang Y, Vaccarella S, Morgan E, Li M, Etxeberria J, Chokunonga E, Manraj SS, Kamate B, Omonisi A, Bray F.Lancet Oncol. 2023 Nov;24(11):1206-1218. doi: 10.1016/S1470-2045(23)00444-8. Epub 2023 Oct 11.PMID: 37837979
  • Global trends in esophageal cancer.

    Malhotra GK, Yanala U, Ravipati A, Follet M, Vijayakumar M, Are C.J Surg Oncol. 2017 Apr;115(5):564-579. doi: 10.1002/jso.24592. Epub 2017 Mar 20.PMID: 28320055
  • Esophageal Cancer: Overview, Risk Factors, and Reasons for the Rise.

    Lander S, Lander E, Gibson MK.Curr Gastroenterol Rep. 2023 Nov;25(11):275-279. doi: 10.1007/s11894-023-00899-0. Epub 2023 Oct 9.PMID: 37812328 Review.
  • Epidemiology of esophageal cancer in Japan and China.

    Lin Y, Totsuka Y, He Y, Kikuchi S, Qiao Y, Ueda J, Wei W, Inoue M, Tanaka H.J Epidemiol. 2013;23(4):233-42. doi: 10.2188/jea.je20120162. Epub 2013 Apr 27.PMID: 23629646 Free PMC article. Review.
See all similar articles

Cited by

  • XRCC2 knockdown effectively sensitizes esophageal cancer to albumin-paclitaxel in vitro and in vivo.

    Xu J, Liu X, Huang Z, Lu T, Zhang Y, Cai D, Li X.Biochem Genet. 2024 Jul 24. doi: 10.1007/s10528-024-10885-4. Online ahead of print.PMID: 39048769
  • Clinicopathologic features and surgical treatment prognosis of esophageal carcinosarcoma.

    Shen J, Lu K, Liu F, Chen X, Chen Q, Wu B, Wang H, Ge P, Han G, Wang F, Zhang P, Yin P, Jia W, Zheng Y, Wang P, Sun F.Front Oncol. 2024 Aug 21;14:1387611. doi: 10.3389/fonc.2024.1387611. eCollection 2024.PMID: 39234394 Free PMC article.
  • SENP3 mediates the activation of the Wnt/β-catenin signaling pathway to accelerate the growth and metastasis of oesophagal squamous cell carcinoma in mice.

    Wang P, Yang L, Guo Y, Qi S, Liang J, Tian G, Tian Z.Funct Integr Genomics. 2024 Feb 22;24(2):40. doi: 10.1007/s10142-024-01321-2.PMID: 38383667
  • Prognostic prediction and comparison of three staging programs for patients with advanced (T2-T4) esophageal squamous carcinoma after radical resection.

    Wang Z, Li F, Zhu M, Lu T, Wen L, Yang S, Zhuang X, Zhang S, Ma Y, Lian J.Front Oncol. 2024 Jun 27;14:1376527. doi: 10.3389/fonc.2024.1376527. eCollection 2024.PMID: 38993638 Free PMC article.
  • Novel dual action PARP and microtubule polymerization inhibitor AMXI-5001 powerfully inhibits growth of esophageal carcinoma both alone and in combination with radiotherapy.

    Brand NR, Yang YW, Ding V, Dutta H, Peto CJ, Lemjabbar-Alaoui H, Jablons DM.Am J Cancer Res. 2024 Jan 15;14(1):378-389. doi: 10.62347/UHLU6598. eCollection 2024.PMID: 38323288 Free PMC article.

Leave a Reply

Your email address will not be published. Required fields are marked *